Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Invigor Medical vs VirtualCare2Go

Two GLP-1 desks, one scoreboard. We put Invigor Medical and VirtualCare2Go head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 9 · Grade B+

Invigor Medical

Visit Invigor Medical Full brief →
vs
No. 111 · Grade C

VirtualCare2Go

Visit VirtualCare2Go Full brief →

The verdict

Invigor Medical takes this head-to-head.

Invigor Medical scores 88 to 72 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.

That doesn't make VirtualCare2Go a bad call — it's best for readers who want same-day compounded semaglutide (injection or oral tablet) with nationwide shipping. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
87
48
Supply Reliability
88
69
Transparency
84
88
Access Breadth
82
96
Clinical Oversight
88
72
Track Record
90
68
Invigor MedicalBrief Score 88 · 72VirtualCare2Go

Price, coverage & the tracker

Invigor MedicalVirtualCare2Go
Brief Score88/100 (B+)72/100 (C)
Semaglutide$199/moFrom $279/mo (starting dose, compounded)
Tirzepatide$339/moFrom $629/mo (starting dose, compounded)
CoverageNot disclosedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.

VirtualCare2Go: New to the tracker on 1 August 2026. The published line reads From $279/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.